S. Michael Rothenberg joins Pfizer Boulder Research Unit

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

S. Michael Rothenberg has joined Pfizer as the head of Early Clinical Development at the Boulder Research Unit.

Prior to joining Pfizer, he was vice president of Research and Development at Loxo Oncology, where he led the overall clinical development of selpercatinib (LOXO-292, ARRY-192), a selective RET kinase inhibitor for patients with RET gene-altered cancers, and the early clinical development of LOXO-305, a next generation BTK inhibitor for patients with B-cell malignancies.

“We are very excited that Dr. Rothenberg has joined Pfizer as the head of Early Clinical Development for the Boulder research unit,” Nicholas A. Saccomano, chief scientific officer of Pfizer Boulder Research & Development, said in a statement. “Given his vast experience in medical oncology and developing targeted oncology agents, we have every reason to believe that his expertise will help Pfizer and the Boulder team bring breakthrough medicines to people living with cancer.”

While at Loxo, Rothenberg worked closely with the team at Array BioPharma, which became the Pfizer Boulder Research Unit after its acquisition in June 2019, on the preclinical development of selpercatinib and the next generation TRK kinase inhibitor LOXO-195. Prior to his work in biotechnology, he was a medical oncologist and cancer researcher at the Massachusetts General Hospital Cancer Center.

Table of Contents

YOU MAY BE INTERESTED IN

I write a weekly blog for Georgetown University’s Lombardi Comprehensive Cancer Center community. Here I share an updated version of a blog post I wrote in September 2024, now supplemented by some poems I have written over the years that inspired paintings by my wife Harriet Weiner, who is a much better artist than I am a poet or writer. 
The Government Accountability Office, an independent, non-partisan congressional watchdog agency, found that NIH violated the Impoundment Control Act of 1974 when it cancelled nearly 2,000 research grants in an effort to comply with several of President Donald Trump’s executive orders, including “Ending Radical And Wasteful Government DEI Programs And Preferencing” (The Cancer Letter, Jan 24, 2025).

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login